Abbott Third Quarter 2025 Results and Highlights

The provided source is an excerpt from a corporate conference call or investor presentation detailing Abbott Laboratories' third-quarter 2025 results and business highlights. Financial data is presented, showing worldwide sales of $11.4 billion and adjusted diluted earnings per share of $1.30, alongside organic sales growth metrics for key business units like Medical Devices and Diagnostics. The document showcases several innovative medical device approvals, including the expanded CE Mark for the Navitor® transcatheter aortic valve system and regulatory approval in Japan for the TriClip® device, which treats leaky tricuspid heart valves. Additionally, the company is addressing the blood supply shortage through a partnership with the Big Ten Conference to promote blood donation. Finally, the source reaffirms the full-year guidance for organic sales growth and adjusted diluted EPS, excluding COVID-19 testing sales.

There are no comments yet.

Please log in to write the first comment.